Compare RNA & BHAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNA | BHAV |
|---|---|---|
| Founded | 2025 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 140.8M |
| IPO Year | 2025 | 2026 |
| Metric | RNA | BHAV |
|---|---|---|
| Price | $6.45 | $10.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 205.6K | 37.8K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $104.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.47 | $9.90 |
| 52 Week High | $73.06 | $10.13 |
| Indicator | RNA | BHAV |
|---|---|---|
| Relative Strength Index (RSI) | 24.72 | 69.40 |
| Support Level | N/A | $10.02 |
| Resistance Level | $8.50 | N/A |
| Average True Range (ATR) | 0.42 | 0.01 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 1.49 | 100.00 |
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
BHAV Acquisition Corp is a blank check company.